

LISTE DES FINANCEMENTS ACCORDÉS PAR L'AFM-TELETHON EN 2023

Au titre de sa mission Guérir (hors financements accordés à Généthon, CECS-Istem, Institut de Myologie)

POLITIQUE D'APPEL D'OFFRES

Projets soumis à l'appel d'offres annuel

Commission thématique : Myologie fondamentale

Aides aux jeunes chercheurs post-doctorants

ANQUETIL	Céline	PARIS	FRANCE	CAchexia and Resident MAcrophages: fate and function study
SMITH	Jacob Anderson Giffen	BARCELONE	ESPAGNE	Influence of circadian regulation on motor neuron-muscle fiber crosstalk

Financements de projets Tremplins

TAYLOR	Michael	CARDIFF	ROYAUME-UNI	Mef2 dynamics in a model muscle injury/repair system
VOLK	Talila	REHOVOT	ISRAËL	The contribution of the LINC complex to epigenetic regulation of chromatin in mature muscle fibers

Financements de projets

BLAAUW	Bert	PADOUE	ITALIE	Identification of muscle-specific factors involved in NMJ maintenance and their regulation by mTORC1
CIENIEWSKI-BERNARD	Caroline	LOOS	FRANCE	Trojan-CryAB: an innovative therapeutic approach for skeletal muscle diseases resulting from proteotoxicity and protein aggregation
DUPREZ	Delphine	PARIS	FRANCE	Regionalisation of myogenesis
LEBRETON	Gaëlle	TOULOUSE	FRANCE	Muscle-hematopoietic organ crosstalk: alary somatic muscle as a secretory organ regulating hematopoiesis in Drosophila.
LEFKIMMIATIS	Konstantinos	PAVIE	ITALIE	The spatiotemporal map of nuclear signalling in the aging muscle
MAMMUCARI	Cristina	PADOUE	ITALIE	The role of mitochondrial calcium signalling in aging skeletal muscle.
MENZIES	Keir	OTTAWA	CANADA	Examining the role and therapeutic potential of Poly-ADP-Ribosylation (PARylation) in myopathies and skeletal muscle maintenance and function
PENDE	Mario	PARIS	FRANCE	Role of mitochondrial YAP and TAZ in muscle growth, regeneration and mechanotransduction
PIERCY	Richard J.	LONDRES	ROYAUME-UNI	Defining dystrophin's transcriptional domains in healthy and damaged muscle
POLGE	Cécile	SAINTE GENÈS CHAMANELLE	FRANCE	Towards the inhibition of skeletal muscle atrophy by selective inhibition of the ad hoc MuRF1- E2 couple
ROMANELLO	Vanina	PADOUE	ITALIE	The in vivo role of peroxisomes in the control of muscle function
SAURIN	Andrew	MARSEILLE	FRANCE	Hox control of Drosophila adult myogenesis
SHI	De-Li	PARIS	FRANCE	Rbm24-controlled cytoplasmic polyadenylation in the post-transcriptional regulation of muscle cell differentiation
SOTIROPOULOS	Athanassia	PARIS	FRANCE	Functional cell heterogeneity underlying muscle plasticity

Commission thématique : Bases Moléculaires et Physiopathologie des Dystrophies Musculaires

Aides aux jeunes chercheurs post-doctorants

APOLLONI	Savina	ROME	ITALIE	Targeting S100A4 to study the macrophages-muscle cells cross-talk in models of Duchenne Muscular Dystrophy
LÉGARÉ	Cécilia	CHICOUTIMI	CANADA	Identification of molecular signatures associated to strength training in myotonic dystrophy type 1

Financements de projets

AMTHOR	Helge	MONTIGNY-LE-BRETONNEUX	FRANCE	The syncytial organization of dystrophin mosaic in female mdx carrier mice
BOUTER	Anthony	PESSAC	FRANCE	Interplay of annexins, macrophages and fibroadipogenic progenitors in the development of muscular dystrophies
COPPEE	Frédérique	MONS	BELGIQUE	Characterization of DUX4 and DUX4c major protein partners to identify new therapeutic targets for faciocapulohumeral muscular dystrophy (FSHD)
CORDERO	Gerardo Antonio	LISBONNE	PORTUGAL	DYSTRO-NET2: Gene Regulatory Networks of LAMA2-CMD Based on Single-nucleus Sequencing
DI PIETRO	Lorena	ROME	ITALIE	DIssecting the pathogenetic RolE played by the different Cell types within the skeletal muscle sTem cell nIche Of FSHD patieNts
LANZUOLO	Chiara	MILAN	ITALIE	Exploring the genetic and epigenetic background underlying the phenotype's variability in Emery Dreifuss Muscular Dystrophy
MAZZONE	Massimiliano	TURIN	ITALIE	GLUD1 as a potential target in Muscular Dystrophy
PARROT	Sandrine	BRON	FRANCE	Alterations in brain glutamate and GABA neurotransmissions in DM1 disease: focus on neuronal subpopulations and related electrophysiological signals
VAN PUTTEN	Maaike	LEIDEN	PAYS-BAS	Characterization of four humanized mouse models for Duchenne muscular dystrophy
WANSINK	Derick G.	NIJMEGEN	PAYS-BAS	DM1 repeat length-dependent disease heterogeneity in muscles
ZAMMIT	Peter	LONDRES	ROYAUME-UNI	Investigating pathogenic mechanisms in FSHD myogenesis.

Commission thématique : Bases moléculaires et physiopathologie des autres maladies neuromusculaires

Aides aux jeunes chercheurs post-doctorants

GABILLARD	Claudie	ANGERS	FRANCE	Modulation of mitochondrial DYNAmics as a therapeutic approach to maintain mtDNA integrity and mitigate the accumulation of deficient myofibers in mitochondrial MYOpathies
JOHARI	Mridul	HELSINKI	FINLANDE	Improved diagnostics and gene discovery for unsolved myopathies
MORETTON	Amandine	AUBIÈRE	FRANCE	Identification and characterisation of new players in mtDNA maintenance in health and disease

Financements de projets

BARIS	Olivier	ANGERS	FRANCE	Modulation of mitochondrial DYNAmics as a therapeutic approach to maintain mtDNA integrity and mitigate the accumulation of deficient myofibers in mitochondrial MYOpathies
BENARD	Giovanni	BORDEAUX	FRANCE	Studying the ribosomal-associated quality control in a mitochondrial syndrome.
BRIS	Céline	ANGERS	FRANCE	Urine-derived cells for non-invasive diagnosis of mitochondrial diseases
CHEVROLLIER	Arnaud	ANGERS	FRANCE	Induced neurons resulting from direct conversion of fibroblasts from patients with mitochondrial diseases: a new model to explore ATP synthase reverse function and its role in mitochondrial fission.
COLLE	Marie-Anne	NANTES	FRANCE	Effects of enzyme replacement therapy on lysosome-autophagosome-mitochondria cross-talk and muscle repair in Pompe disease (LYSAUMI)
COSSEE	Mireille	MONTPELLIER	FRANCE	Transcriptomic and proteomic analyses to unravel pathophysiology and Phenotype-Genotype Correlations in Patients with skeletal Titinopathies
DE LONLAY	Pascale	PARIS	FRANCE	Autophagy dysregulation in acute rhabdomyolysis
FARGE	Geraldine	CLERMONT-FERRAND	FRANCE	Exploring at the single molecule level the functional consequences of disease-causing mutations in human mitochondrial DNA maintenance and expression factors
FERNANDEZ-VIZARRA	Erika	PADOUÉ	ITALIE	Tissue-specificity of complex III dysfunction in mitochondrial encephalomyopathies
RAAPHORST	Joost	AMSTERDAM	PAYS-BAS	Auto-immunity and muscle strength: the effect of anti-SRP and anti-HMGCR antibodies on myofiber contractility in myositis
ROSSI	Daniela	SIENNE	ITALIE	CCDC78: from basic research to mechanisms of disease
STEFFANN	Julie	PARIS	FRANCE	MITOCARE: Mitochondrial replacement therapy (MRT) against mitochondrial DNA (mtDNA) disorders: are we far from its clinical application?
UDD	Bjarne	HELSINKI	FINLANDE	Titinopathies – disease models for translational therapeutics
VANDROMME	Marie	TOULOUSE	FRANCE	Epigenetic contribution in the etiology of Myotubular Myopathy

Commission thématique : Système nerveux - Motoneurone et jonction neuromusculaire

Aides aux jeunes chercheurs post-doctorants

KLEIJWEGT	Constance	MONTPELLIER	FRANCE	Chromatin proteomics of extended GAA/TTC trinucleotides repeats : Implication for Friedreich Ataxia
MAINO	Eleonora	BALE	SUISSE	Characterization of pathophysiological mechanisms involved in the selective vulnerability of muscles in Myasthenia Gravis
REICHOVA	Alexandra	BORDEAUX	FRANCE	Oxytocin and 5-HT involvement in early dysregulation of the chloride homeostasis in spinal ALS motoneurons
SARDINA	Francesca	ROME	ITALIE	Phenotypic evaluation of microtubules network as prognostic and predictive marker in response to spastin elevating approaches in Hereditary Spastic Paraparesis type 4

Financements de projets Tremplins

CANDAYAN NIRON	Ayse	ANVERS	BELGIQUE	Investigation of NGS-intractable mutational classes in peripheral neurodegeneration
RODRIGUEZ CRUZ	Pedro M.	BARCELONA	ESPAGNE	A global analysis of the CMT1A locus: implications for the origin and susceptibility to Charcot-Marie-Tooth disease type 1A across populations

Financements de projets

ARRIBAT	Yoan	MONTPELLIER	FRANCE	Organelle coordination in hereditary spastic paraparesis: deciphering protein network and restoring lipid balance
BESSEREAU	Jean-Louis	LYON	FRANCE	Genetic control of acetylcholine receptor expression: from new mechanisms to functional genomics
BRANCHEREAU	Pascal	BORDEAUX	FRANCE	Chloride-related inhibition in spinal motoneurons during the ALS disease progression in mouse model
DÍAZ-MANERA	Jordi	NEWCASTLE	ROYAUME-UNI	Transcript-MND: Transcribing the process of muscle degeneration in patients with motor neuron diseases
FERRARO	Elisabetta	PISE	ITALIE	Metabolic reprogramming and activation of microglia in amyotrophic lateral sclerosis (ALS): a pivotal role for serotonin?
HAASE	Georg	MARSEILLE	FRANCE	Mini-Brains to Better Understand C9orf72-linked ALS
JORDANOVA	Albena	EDEGEM	BELGIQUE	Profiling the spatial RNA and protein signatures of peripheral neurons in YARS associated Charcot-Marie-Tooth neuropathies
LIEVENS	Jean-Charles	MONTPELLIER	FRANCE	Deciphering the beneficial effects of Sigma-1 receptor in amyotrophic lateral sclerosis
ORTEGA CANO	Juan Alberto	L'HOSPITALET DE LLOBREGAT	ESPAGNE	Defining the contribution of ALS-associated alterations in motor neuron microenvironment to disease pathogenesis.
OURY	Franck	PARIS	FRANCE	Decipher the role of the Ocn-induced autophagy in motoneurons and its anti-aging therapeutic potential
PENNUTO	Maria	PADOUE	ITALIE	Development of a therapeutic strategy to suppress LSD1 and PRMT6-mediated toxic gain of function in SBMA
POLETTI	Angelo	MILAN	ITALIE	The involvement of the small heat shock protein HSPB8 in amyotrophic lateral sclerosis
RINALDO	Cinzia	ROME	ITALIE	Spastin elevating approaches to counteract Hereditary Spastic Paraparesis
SELLIER	Chantal	STRASBOURG	FRANCE	Identify the role of NUP50 in motor neuron physiology and ALS pathology
VIERO	Gabriella	POVO (TRENTE)	ITALIE	Ribosome-based functions of the SMN protein: from fundamental biology to second-generation therapies for SMA

Commission thématique : Cellules souches

Aides aux jeunes chercheurs post-doctorants

TESTA	Stefano	MARSEILLE	FRANCE	3D bioprinting for human artificial skeletal muscle modeling
-------	---------	-----------	--------	--

Financements de projets Tremplins

CANTONE	Irene	NAPLES	ITALIE	Understanding X chromosome reactivation in differentiated human muscle cells for a future therapy of X-linked neuromuscular diseases
---------	-------	--------	--------	--

Financements de projets

DUTEIL	Delphine	ILLKIRCH	FRANCE	Role of androgens in muscle regeneration
ELVASSORE	Nicola	PADOUE	ITALIE	Intravital 3D bioprinting approach for muscle stem cell delivery
FUKADA	So-Ichiro	SUITA	JAPON	Identification of factors inducing MuSC expansion from overloaded muscle
LI	Zhenlin	PARIS	FRANCE	Involvement of synemin in cardiomyopathies using human induced pluripotent stem cells (hiPSC) and cell type-specific knock-out murine models
MODTAHEDI	Nazanine	VILLEJUIF	FRANCE	Regulation of the AIF/CHCHD4-dependent mitochondrial import pathway in human skeletal muscle stem cells
OLGUIN	Hugo	SANTIAGO	CHILI	Nedd4-1 promotes regeneration by regulating autophagy in differentiating muscle stem cells.
TIMMERMAN	Vincent	ANVERS	BELGIQUE	Development of a neuromuscular system for testing therapeutic molecules in axonal Charcot-Marie-Tooth neuropathy
ZAMMIT	Peter	LONDRES	ROYAUME-UNI	Induced Pluripotent Stem Cell models to decipher pathomechanisms in FSHD

Commission thématique : Thérapie Génique et/ou Cellulaire des Maladies Rares

Aides aux jeunes chercheurs post-doctorants

AKINYELE	Oluwaseun	PITTSBURGH	USA	Development of a Gene Therapy Approach in an Inborn Error of Polyamine Metabolism
ALMEIDA	Camila	COLUMBUS	USA	Evaluation of AAV9.U7snRNAs in Myotonic Dystrophy type 1 preclinical mouse models
BOFFA	Iolanda	NAPLES	ITALIE	New gene therapy strategies for the treatment of gyrate atrophy of the choroid and retina (GACR), a progressive retinopathy due to the deficiency of the enzyme ornithine amino-transferase
GILLES	Melissa	MONTPELLIER	FRANCE	Treatment of autosomal dominant retinitis pigmentosa caused by G56R mutation in NR2E3 using CRISPR/Cas allele-specific knockout
LÉGER	Elise	PARIS	FRANCE	Optogenetic engineering of stem cell-derived photoreceptors to improve visual restoration
ZANIN	Sofia	PARIS	FRANCE	Gene therapy cure for mitochondrial disease caused by mutations in the mitochondrial RNA stability factor LRPPRC

Financements de projets Tremplins

CARRELLA	Sabrina	NAPLES	ITALIE	OxymiRs modulation as gene-independent therapeutic approach in rare mitochondrial diseases
DARBEY	Annalucia	LONDRES	ROYAUME-UNI	A Muscle Targeted Gene Therapy for Kennedy's Disease
PERDIGÃO	Pedro	COIMBRA	PORTUGAL	Engineering RNA-Targeting CRISPR/Cas13 for the Treatment of Spinocerebellar Ataxia Type 3
RICHARD	Guy-Franck	PARIS	FRANCE	Single-chain antibodies against pathogenic CTG/CUG repeats: diagnosis and therapeutic applications for myotonic dystrophy

Financements de projets

BIONDI	Olivier	EVRY	FRANCE	Role of precision exercise in enhancing gene therapy efficacy in Limb Girdle Muscular Dystrophies
BRUNETTI-PIERRI	Nicola	POUZZOLES	ITALIE	Gene therapy for Wolman disease
GOYENVALLE	Aurélie	MONTIGNY-LE-BRETONNEUX	FRANCE	Evaluation of HDAC inhibitors to increase dystrophin rescue in DMD following exon skipping therapy
LOLLO	Giovanna	VILLEURBANNE	FRANCE	Lipid nanoparticles delivery of antisense oligonucleotides to correct the pathological cause of muscular dystrophies
MOREAU-GAUDRY	François	PESSAC	FRANCE	Development of novel Cas9-nickases for gene therapy of rare genetic diseases: application to the congenital erythropoietic porphyria
MURO	Andrés F.	TRIESTE	ITALIE	Combination of mRNA-LNP and gene targeting approaches as a potential cure for early onset severe Ornithine transcarbamylase deficiency
PIGUET	Françoise	PARIS	FRANCE	Combined gene therapy approach for Pelizaeus Merzbacher disease
ROSSI	Andrea	DÜSSELDORF	ALLEMAGNE	Small molecules that enhance Prime Editing in therapeutic applications
TASFIAOUT	Hichem	SEATTLE	USA	Expression of large dystrophins using AAV and split inteins
WEIN	Nicolas	COLUMBUS	USA	Preclinical evaluation of AAV.U7snRNAs in Myotonic Dystrophy type 1 mouse models

Commission thématique : Thérapie Pharmacologique des maladies neuromusculaires et Recherche Translationnelle

Financements de projets Tremplins

BERLAND	Chloé	PARIS	FRANCE	Novel animal behavior tracking solutions to predict neuromuscular disorders
DOBROWOLNY	Gabriella	ROME	ITALIE	Deconvoluting human ALS muscle environment by Spatial Transcriptomics
VILLA	Chiara	MILAN	ITALIE	Investigating molecular mechanisms underlying dose effects of gold nanoclusters in Friedreich Ataxia

Financements de projets

BADRISING	Umesh	LEIDEN	PAYS-BAS	Optimism for Inclusion Body Myositis: a double-blind randomized placebo-controlled clinical trial with Sirolimus to halt disease progression
CHARTRAND	Pascal	MONTREAL	CANADA	Pre-clinical testing of novel pharmacological inhibitors of toxic DMPK mRNA in a DM1 mouse model
CORDERO-ERAUSQUIN	Matilde	STRASBOURG	FRANCE	Counteracting cortical hyperexcitability as a therapeutical avenue for ALS
D'ANTONIO	Maurizio	MILAN	ITALIE	Targeting the P-eIF2alpha/PPP1R15A branch of the UPR with IFB-088 as a therapeutic strategy in adult CMT1A/B mice
DEVAUX	Jérôme	MONTPELLIER	FRANCE	Pathogenic mechanisms of anti-neurofascin 155 IgG4: Role of bivalence and novel therapeutic approaches.
DORCHIES	Olivier	GENEVE	SUISSE	Duchenne muscular dystrophy: Phenotyping and validation of better murine models for improving preclinical research and clinical translation – a step further
HORNSTEIN	Eran	REHOVOT	ISRAËL	microRNA biomarkers for ALS progression
LAZARIDIS	Konstantinos	ATHENES	GRÈCE	Preclinical study of antigen-specific tolerance induction for the treatment of myasthenia gravis
NARDO	Giovanni	MILAN	ITALIE	Allosteric agonism of purinergic P2X7 receptor as a pharmacological approach to enhance skeletal muscle regeneration in Spinal Bulbar Muscular Atrophy
NOGALES-GADEA	Gisela	BADALONE	ESPAGNE	DM1-HEART-EXTEND: Extending the search for biomarkers of heart damage in Myotonic Dystrophy 1
PHYLACTOU	Leonidas	NICOSIE	CHYPRE	Identifying unique characteristics of Extracellular Vesicles circulating in Myotonic Dystrophy type 1 patients and their use as blood based biomarkers
PISTOCCHI	Anna	SEGRATE	ITALIE	Improving the effects of HDAC8 inhibition by combining the activation of SIRT1 in a zebrafish model of Duchenne muscular dystrophy
RYBALKA	Emma	MELBOURNE	AUSTRALIE	Toward the Clinic: Evaluating the long-term efficacy of re-purposed dimethyl fumarate for the treatment of Duchenne Muscular Dystrophy
SAENZ PENA	Amets	SAINT-SEBASTIEN	ESPAGNE	Wnt signaling pathway activation in muscular dystrophy models: a search of therapeutic use in LGMDR1 muscular dystrophy
SPINAZZI	Marco	ANGERS	FRANCE	THERAPEUTICAL TRIAL EFFICACY OF IMMUNE MODULATION BY LEUKOCYTE DEPLETION IN A MOUSE MODEL OF LEIGH SYNDROME

Commission thématique : Recherche Médicale

Financements de projets

BONNYAUD	Céline	GARCHES	FRANCE	New endpoints on neuromuscular impairments, locomotor and postural control (motor) functions in patients with Late-onset Pompe disease
SACCONI	Sabrina	NICE	FRANCE	New clinical outcome measures to evaluate non-ambulant FSHD patients
SERGEANT	Nicolas	LILLE	FRANCE	Assessment of central nervous system neurodegeneration and impact of type II diabetes in Myotonic Dystrophy type I
TASCA	Giorgio	ROME	ITALIE	Natural history of distal and myofibrillar myopathies assessed by clinical and technological outcome measures: a new toolbox for clinical trials
VOET	Nicole	NIJMEGEN	PAYS-BAS	Testing a tailored Home Exercise program to Gain insight into performance fatigability and Reduce fatigue In Patients with FSHD: THE GRIP on FSHD study
VUILLEROT	Carole	LYON	FRANCE	Development and validation study of a Motor Function Measure digitalized playful completion modules

Appel d'offres Doctorants

AMMAR	Nourhene	RENNES	FRANCE	Live-imaging of adult muscle stem cell activation in Drosophila
BATAILLARD	Méghane	CASTELNAU-LE-LEZ	FRANCE	Systemic gene therapy using NCS1 for treating Wolfram syndrome
BOURGETON	Tiffany	NANTES	FRANCE	Effect of Enzyme replacement therapy (ERT) on skeletal muscle pathophysiology in Pompe disease : specific focus on satellite cells and autophagy
D'AGATA	Léna	PESSAC	FRANCE	Annexins as genetic modifiers of human muscular dystrophies
DAY	Lucie	PARIS	FRANCE	Role of ADAR1 and RNA editing in peripheral myelin maintenance
DELAFENETRE	Arnaud	POITIERS	FRANCE	Functional characterization of muscle cells derived from healthy and DMD human induced Pluripotent Stem Cells: focus on calcium release channels
DELEPINE	Georges	OTTIGNIES-LOUVAIN-LA-NEUVE	BELGIQUE	Role of Hox proteins in the development of adult tubular muscle in Drosophila melanogaster
DELIVRY	Léa	PARIS	FRANCE	Analysis of the transcriptional networks and cellular communications during skeletal muscle hypertrophy
GIL HERNANDEZ	Esther Aurora	BURES-SUR-YVETTE	FRANCE	Functional interplay between the mitochondrial fusion and the lipid transport machineries at ER-mitochondria contact sites
GISBERT	Vincent	MONTPELLIER	FRANCE	Organelle alterations converge on neurodegeneration and lack of regeneration in hereditary spastic paraparesis
HAUTBOIS	Marie	PARIS	FRANCE	Base editing-mediated correction of recurrent mutations in COL7A1 to treat RDEB
HOUQUES	Chloé	MONTPELLIER	FRANCE	Combinatorial treatment with gene and cell therapy for the treatment of SCID
MAIELLANO	Greta	LYON	FRANCE	Role of the TMED proteins in acetylcholine receptor biosynthesis and implication in neuromuscular diseases
PHONGSAVANH	Xaysongkhame Micky	MONTIGNY-LE-BRETONNEUX	FRANCE	Evaluation of HDAC inhibitors to increase dystrophin rescue in DMD following exon skipping therapy
ROUÉ	Clémence	MONTPELLIER	FRANCE	Autoimmune Nodopathy : DEtermine the Roles Of ADAM10/17 in Neuropathy
ROUSSET	Célia	MARSEILLE	FRANCE	Defining the unique developmental program of the trapezius muscle
RUBENS	Paula	PARIS	FRANCE	DNA Methylation Landscape of Normal, Mitochondrial Mutated, and Three-Parent Preimplantation Embryos
THIBAUT	Chloé	BORDEAUX	FRANCE	Development of novel Cas9-nickases for gene therapy of rare genetic diseases: application to the congenital erythropoietic porphyria
VAHDAT	Juliette	MARSEILLE	FRANCE	Exploring ventricular conduction system structure and function in DMD mouse models
VAUCOURT	Mathilde	TOULOUSE	FRANCE	Selective autophagy in X-linked centronuclear myopathy: molecular mechanisms and pathophysiological relevance

Projet soumis à l'appel d'offres thématique ARN médicament et cible

NAMY	Olivier	ORSAY	FRANCE	Translectin: A new termination codon readthrough inducer to expand therapeutics choices for nonsense genetic diseases
-------------	----------------	-------	--------	---

Projets soumis à l'appel d'offres thématique Médecine Mitochondriale

DELEIDI	Michela	PARIS	FRANCE	NAD supplementation for mitochondrial disease therapy
DELETTRE-CRIBAILLET	Cécile	MONTPELLIER	FRANCE	Development of novel molecule derived from polyamines to treat mitochondrial optic neuropathies
LEPELLEY	Alice	PARIS	FRANCE	Anti-interferon therapeutic strategies for primary mitochondrial disorders
MARTI	Ramon	BARCELONE	ESPAGNE	Deoxyribonucleosides as a potential therapy for mitochondrial DNA maintenance disorders
PRIGIONE	Alessandro	DÜSSELDORF	ALLEMAGNE	iPSC-driven repositioning of Sildenafil for treating Mitochondrial Disorders
PROCACCIO	Vincent	ANGERS	FRANCE	Therapeutic strategies targeting mitochondrial dysfunction and inflammation in mitochondrial diseases
TRIFUNOVIC	Aleksandra	COLOGNE	ALLEMAGNE	Regulation of CLPP protease as a treatment for Mitochondrial Diseases

Partenariats institutionnels

BOUKHATMI	Hadi	PARIS	FRANCE	Programme ATIP-Avenir
DUPONT	Jean-Baptiste	PARIS	FRANCE	Programme ATIP-Avenir
KIM	Minchul	PARIS	FRANCE	Programme ATIP-Avenir
LAUGEL	Vincent	STRASBOURG	FRANCE	Cohorte de suivi longitudinal SMA-DNN: Dépistage néonatal de l'Amyotrophie Spinales - Projet pilote SMA-DNN France

Partenariats associatifs

MUSCULAR DYSTROPHY UK		LONDRES	ROYAUME-UNI	Third year of the Collagen VI Alliance Call : - Trial readiness for Collagen VI Myopathies - STRAUB Volker
SMA Europe		CHIPPING CAMPDEN	ROYAUME-UNI	11 th international Call for SMA Research Projects
Cure CMD		TORRANCE	USA	Targeting Primary Cilium-Related Molecular Pathways to Correct Tendon Cell Defects in Collagen VI Congenital Muscular Dystrophies - CENNI Vittoria
IRME		PARIS	FRANCE	Aging and Controlling the Fate of Human Spinal Cord stem cells - HUGNOT Jean-Philippe
RETINA France		COLOMIERS	FRANCE	- Approches de thérapie oligonucléotidique antisens et de thérapie génique pour le traitement des maladies dégénératives rétiniennes en ciblant la voie glycogène synthase kinase 3 - ROGER Jérôme - Régénération de la rétine : interaction entre les cellules de Müller et la microglie - PERRON Muriel
Vaincre La Mucoviscidose (VLM)		PARIS	FRANCE	Appel à projets scientifiques 2023 : - Evaluation d'une stratégie thérapeutique à base d'oligonucléotides pour des patients CF non éligibles aux modulateurs CFTR - CADARS Magali - AV6.2FF : nouvelle opportunité de thérapie génique à tropisme pulmonaire pour traiter tous les patients atteints de mucoviscidose - TABARY Olivier
Vaincre les Maladies Lysosomales (VML)		MASSY	FRANCE	Appel à projets de recherche 2023 : Enzyme replacement therapy by cell encapsulation for metachromatic leukodystrophy - PIGUET Françoise

Projets soumis en dehors du calendrier AO ou sortis de l'AO pour des raisons de PI

BRUNETEAU	Gaelle	PARIS	FRANCE	Cell signaling, Reinnervation and Metabolism in Amyotrophic Lateral Sclerosis (CERMALS)
------------------	---------------	-------	--------	---

Projets Ignition

BUNING	Hildegard	HANNOVRE	ALLEMAGNE	Rational-designed enveloped AAV: a novel all-in-one gene transfer system
DECRESSAC	Michael	LA TRONCHE	FRANCE	Towards gene replacement tHErapy for sevRE mitochondrial diSEase
DUMONT	Nicolas	MONTREAL	CANADA	Muscle stem cell defects in Myotonic Dystrophy Type 1: physiopathology and therapeutic avenues
FERNANDEZ-COSTA	Juan M.	BARCELONE	ESPAGNE	Monitoring of fibrotic processes in 3D skeletal muscle co-cultures for Muscular Dystrophies using plasmonic biosensors
MUSARO	Antonio	ROME	ITALIE	Understanding the contribution of molecular mediators of inflammation to DMD progression and implications for therapy: studying the impact of IL-6 transsignaling on dystrophic muscle stability
PALACIOS	Daniela	ROME	ITALIE	Functionalized nanoparticles for targeted genome editing in Duchenne Muscular Dystrophy
SUMARA	Izabela	ILLKIRCH	FRANCE	Therapeutic dissolution of aberrant nucleoporin condensation in Fragile X syndrome using gene therapy approaches
VISCOMI	Carlo	PADOUE	ITALIE	Harnessing mitophagy to treat mitochondrial myopathies

ACTIONS STRATEGIQUES

Projets stratégiques

AGBULUT	Onnik	PARIS	FRANCE	Innovative bio-inspired cell and tissue models of genetic dilated cardiomyopathy for disease modelling and drug discovery
BOMONT	Pascale	LYON	FRANCE	Therapy for Giant Axonal Neuropathy
CORRAL-DEBRINSKI	Marisol	PARIS	FRANCE	Neuroglobin gene overexpression: a promising tool for treating a large spectrum of neurological disorders thanks to its ability to safely and sustainably preserve mitochondrial integrity
DUMONCEAUX	Julie	LONDRES	ROYAUME-UNI	DUX4 in FSHD: pathophysiology and therapeutic approaches
GALY	Anne	CORBEIL-ESSONNES	FRANCE	Sickle cell disease gene therapy program
HUDA	Ruksana	GALVESTON	USA	Developing mAb-siRNA conjugate for therapy of myasthenia gravis
LAPORTE	Jocelyn	ILLKIRCH	FRANCE	Pathophysiology and therapeutic proof-of-concepts for congenital myopathies
MALFATTI	Edoardo	CRÉTEIL	FRANCE	UPHold - Ultrarare PYROXD1, ACTN2, and FHL1 congenital-myopathies Pharmacological treatment through iPSC-based Drug repurposing
OLIVIER	Sophie	EVRY	FRANCE	Preclinical and clinical development of gene therapy candidates for the treatment of LGMD-R9, LGMD-R5 and LGMD-R1
OLIVIER-FAIVRE	Laurence	DIJON	FRANCE	PERIGENOMED-CLINICS 1: a pre-pilot to assess the feasibility and acceptability of newborn screening using panel-based genome sequencing in France
POURQUIE	Olivier	BOSTON	USA	Toward cell therapy for Duchenne Muscular Dystrophy: characterization of regenerative potential of hIPS derived Pax7+ cells
PROCACCIO	Vincent	ANGERS	FRANCE	Identifying candidate drugs in mitochondrial cardiomyopathies: From Mouse to Human
STURTZ	Franck	LIMOGES	FRANCE	NeuroCur-2 project - Pursuing the development of a curcumin-based nanoparticle treatment for patients with peripheral neuropathies
VAILLEND	Cyrille	ORSAY	FRANCE	DECODING CENTRAL DEFECTS IN DYSTROPHINOPATHIES : FROM DIAGNOSTIC TO REMEDIATION
VILQUIN	Jean-Thomas	PARIS	FRANCE	Comparative study of iPSC-derived myogenic precursors proposed for cell therapy in a model of Duchenne muscular Dystrophy

Pôles stratégiques

LACAMPAGNE	Alain	MONTPELLIER	FRANCE	Liste des pathologies principalement étudiées : Dystrophies musculaires : DMD / BMD / FSHD ; Titinopathies ; Syndrome de pseudo-obstruction intestinale chronique ; Dyskinésie ciliaire primitive ; Mucoviscidose ; Sarcopénie
MAGGINIER	Frédérique	MARSEILLE	FRANCE	Liste des pathologies principalement étudiées : Pathologies liées au gène STIM1 ; Dysferlinopathies ; CMT ; FSHD ; Cardiomyopathies génétiques (LMNA ; Rasopathies...) ; Encephalopathie épileptique KCQN2 ; Syndrome de Rett ; Pathologies du vieillissement (Progeria, progeria like, MADA syndrome, Hallermann-Streiff syndrome...) ; David syndrome
RELAIX	Frédéric	CRETEIL	FRANCE	Liste des pathologies principalement étudiées : Dystrophies musculaires : DMD / FSHD ; SMA ; Myopathies congénitales ; Myopathies inflammatoires
SCHAEFFER	Laurent	LYON	FRANCE	Liste des pathologies principalement étudiées : Dystrophies musculaires : DMD / DM1 ; Myopathies inflammatoires ; Myopathie centronucléaire ; Myopathies congénitales / Myopathie congénitale à « central cores » ; Hyperthermie maligne ; Ataxies, dont Ataxie de Friedreich ; Maladies du motoneurone (SLA / SMA / CMT) ; Myasthénie ; Neuropathies sensorielles

Structures stratégiques

FONDATION MALADIES RARES	Fmr	PARIS	FRANCE	Appel à projets auprès des Filières de Santé Maladies Rares : '- Orai1 Ca2+ channel: a new therapeutic target in PAH - ANTIGNY Fabrice '- Promoting regenerative inflammation to improve muscle homeostasis in Duchenne Muscular Dystrophy - CHAZAUD Bénédicte '- Consolidation of an innovative strategy for the treatment of calcitriol-mediated hypercalcemia - LAVERNY Gilles '- Inducing albumin-mediated recycling of endogenous proteins: a novel strategy to treat quantitative deficiencies of plasma proteins - LENTING Peter '- HDAC6 inhibitors to treat Duchenne Muscular Dystrophy - SCHAEFFER Laurent
FONDATION MALADIES RARES	Fmr	PARIS	FRANCE	Subvention 2023
GENOPOLE	Genopole	EVRY	FRANCE	Participation financière de l'AFM au budget 2023 du GIP GENOPOLE

Outils stratégiques

BASSEZ	Guillaume	PARIS	FRANCE	International Myotonic Dystrophy Registry - iDM-Scope
SACCONI	Sabrina	NICE	FRANCE	French national registry for FacioScapuloHumeral muscular Dystrophy (FSHD)

Plateformes stratégiques

SOLE	Guilhem	BORDEAUX	FRANCE	Plateformes d'essais thérapeutiques Pédiatriques et Adultes Neuromusculaires - BORDEAUX
------	---------	----------	--------	---

AUTRES ACTIONS

Manifestations scientifiques (congrès, colloques)

BOUTHEMY	Mathieu	PARIS	FRANCE	SLA & maladies du motoneurone : quelles pistes pour demain ?
CHARRETON	Amandine	RENNES	FRANCE	Séminaire de Génétique de l'Ouest - "Thérapies et enjeux sociétaux"- 14&15 septembre 2023 (Le Croisic)
CHAZAUD	Bénédicte	LYON	FRANCE	Final Meeting of the European Network RENOIR "From tissue repair to Bio-engineering in skeletal and cardiac muscles"
GOMEZ	Ana Maria	CHÂTENAY-MALABRY	FRANCE	Gordon Research Conference : "Muscle: excitation-contraction coupling"
KAN	Hermien	LEIDEN	PAYS-BAS	Fourth International Imaging in Neuromuscular Disease Conference 2023
KINOSHITA	June	LEXINGTON	USA	30 th Annual International Congress on FSHD
LAFUSTE	Peggy	CRETEIL	FRANCE	From basic discovery to preclinical modeling: at the forefront of muscle disease therapies
MOURIKIS	Philippos	CRETEIL	FRANCE	Frontiers in Myogenesis Conference Advances in Skeletal Muscle Growth, Repair and Disease
PEREZ DE CASTRO	Ignacio	MADRID	ESPAGNE	4 th International Meeting on Laminopathies
SORCI	Guglielmo	PEROUSE	ITALIE	20 th IIM international meeting
VAN ENGELEN	Baziel	NIJMEGEN	PAYS-BAS	IDMC-14 International myotonic dystrophy symposium number 14

Plateformes

DESVIGNES	Cyril	MEZILLES	FRANCE	Financement CEDS
------------------	--------------	----------	--------	------------------